Overview
- The new indication covers once‑daily oral deucravacitinib 6 mg for adults with active psoriatic arthritis.
- Across POETYK PsA‑1 and PsA‑2, 54% on deucravacitinib achieved ACR20 at week 16 versus 34%–39% with placebo.
- Minimal disease activity at week 16 improved with deucravacitinib, reaching 19% vs 10% in PsA‑1 and 26% vs 15% in PsA‑2.
- Trials enrolled biologic‑naive patients and those previously treated with TNF inhibitors, with PsA‑2 including an apremilast safety reference arm.
- Common adverse reactions included upper respiratory infections, increased creatine phosphokinase, herpes simplex, mouth ulcers, folliculitis, and acne, with label warnings for infections, malignancy risk, laboratory abnormalities, rhabdomyolysis, and immunization considerations.